Below is a segment of
an article
appearing in the
January 2007 issue of
PRACTICAL Neurology.
Written by Stephen D. Silberstein, MD, it
describes the
current understanding of migraine pathophysiology.
Comments and insights
provided by
James P. Boyd, DDS appear in the right-side column
to further enhance the general dentist's
understanding of the NTI-tss' role in migraine prevention.
|

|
Deepen Your Understanding of
Headache
By Stephen D.
Silberstein, MD
The current consensus is that the
term chronic daily headache (CDH) refers to headache disorders experienced very
frequently (15 or more days a month), including headaches associated with
medication overuse. CDH can be divided into primary and secondary varieties.1 Studies in the United States, Europe and Asia
suggest that four to five percent of the general population have primary CDH,2-4 and 0.5 percent have severe
headaches daily.5-7
Once secondary headache, including
medication overuse headache (MOH), has been excluded, frequent headache
sufferers are subdivided into two groups, based on headache duration. When the
duration is greater than four hours, the major primary disorders to consider
are chronic migraine (CM), hemicrania continua (HC), chronic tension-type
headache (CTTH) and new daily persistent headache (NDPH). CM, NDPH, and HC are
primary CDH disorders that are now included in the 2nd IHS classification.8 Transformed migraine
(TM) is similar, but not identical, to CM. Understanding and identifying the
multifarious presentations that fall under the rubric of CDH is further
complicated by its rather esoteric pathophysiology. In this article, we will
look more closely at the mechanisms at work beneath the surface.
Pathophysiology
Of Chronic Daily Headache
The trigeminal nucleus caudalis
(TNC) of the trigeminal complex, the major relay nucleus for head and face
pain, receives nociceptive input from cephalic blood vessels and pericranial
muscles (via the trigeminal and upper cervical nerves)A, as well as inhibitory and
facilitatory suprasegmental input. The trigeminal nerve has three divisions:
ophthalmic, mandibular and maxillary. Anterior pain-producing structures are
innervated by the ophthalmic (first) division.B
Posterior regions are subserved by the upper cervical nerves.9
Afferent processes of the trigeminal
nerve converge to form the sensory root, entering the brain stem at the pontine
level and terminating in the trigeminal brain stem nuclear complex, which is
composed of the principal and the spinal trigeminal nuclei (subdivided into the
nucleus oralis, the subnuclear interpolaris, and the nucleus caudalis). The
brain stem spinal trigeminal nucleus is analogous to the dorsal horn of the
spinal canal, the first synapse in the central nervous system.
Most spinothalamic and
trigeminothalamic tract neurons that originate from the dorsal horn and project
to ventroposterior lateral and ventroposterior medial nuclei have wide dynamic-range
characteristics.10
The trigeminothalamic tract is analogous to the spinothalamic tract.
Second-order neurons from the trigeminal spinal nuclei form the
trigeminothalamic tract and project to other midbrain structures, as well as to
the thalamic tract. Most ventroposterior medial nuclei, some with wide
dynamic-range characteristics, respond to low-threshold stimuli.9 Recent evidence
suggests that central pain facilitatory neurons (on-cells) are present in the
ventromedial medulla. In addition, neurons in the TNC can be sensitized as a
result of intense neuronal stimulation.
Pain has three spatiotemporal
characteristics: (1) as intensity increases, the area in which it is
experienced often enlarges (radiation); (2) pain may outlast the evoking
stimulus; and (3) repeated nociceptive stimuli D
may increase the perceived pain intensity, even without increased input
(sensitization).11
Pain has both sensory and affective dimensions. In addition to being physically
unpleasant, pain is associated with negative emotional feelings shaped by
context, anticipations and attitudes.10 Pain unpleasantness
is in series with pain sensation intensity.
Headache
Pathophysiology
Pain in Migraine
Migraine
most likely results from a dysfunction of the trigeminal nerveE and its central connections that
normally modulate sensory input. Components involved include: (1) the cranial
blood vessels and meninges; (2) the trigeminal innervation of the vessels and
meninges; (3) the reflex connections of the trigeminal system with the cranial
parasympathetic outflow; and (4) local and descending pain modulation.F The key pathway for the
pain is trigeminovascular input from the meningeal vessels. Brain imaging
studies suggest that important modulation of the trigeminovascular nociceptive
input stems from the dorsal raphe nucleus, locus coeruleus and nucleus raphe
magnus.12
Although the source of pain in CDH
is unknown and may depend on the subtype, recent work suggests several
mechanisms:
(1) increased peripheral nociceptive
activation (perhaps due to chronic neurogenic inflammation) G and activation of silent nociceptors;
(2) peripheral sensitization; (3) altered sensory neuron excitability due to
changes in ion-channel expression/ phosphorylation/accumulation in primary
afferents; (4) central sensitization of TNC neurons due to posttranslational
changes in ligand- and voltage-gated ion-channel kinetics, altering excitability
and strength of their synaptic inputs; (5) phenotype modulation due to
alterations in the expression of receptors/transmitters/ion channels in
peripheral and central neurons; (6) synaptic reorganization modification of
synaptic connections caused by cell death or sprouting; (7) decreased pain
modulation due to loss of local and descending input;11 or (8) a combination
of these.
Peripheral Mechanisms
Although the brain itself is largely
insensate, pain can be generated by large cranial vessels, proximal
intracranial vessels or dura mater. The central convergence of the ophthalmic
division of the trigeminal nerve and the branches of C2 nerve roots explain the
typical distribution of migraine pain over the frontal and temporal regions and
the referral of pain to the parietal, occipital and high cervical regions.12
During a migraine attack, an
inflammatory process occurs in the meninges, at the site of the nerve terminal.
Trigeminal nerve activation is accompanied by the release of vasoactive
neuropeptides, including CGRP, substance P (SP) and neurokinin A from the nerve
terminals. These
mediators produce mast cell activation, sensitization of the nerve terminals
and extravasation of fluid into the perivascular space around the dural blood
vessels. Intense neuronal stimulation causes induction of c-fos (an immediate
early gene product) in the TNC of the brainstem. SP and CGRP further amplify
the trigeminal terminal sensitivity by stimulating the release of bradykinin
and other inflammatory mediators from nonneuronal cells.13
Inflammatory
mediators increase the responsiveness of and turn on silent, or sleeping,
nociceptors. Neurotropins, such as nerve growth factor, are synthesized locally
and can also activate mast cells and sensitive nerve terminals.14 Bradykinin and
kallidin, both acting through the B1 and B2 receptors, can activate primary
afferent nociceptors.15
Prostaglandins and nitric oxide (a diffusible gas that acts as a
neurotransmitter)16
are both endogenous mediators that can be produced locally and can sensitize
nociceptors. Cortical spreading depression (the cause of the aura) can activate
the trigeminal system.
Repeated episodes of neurogenic inflammation may chronically sensitize the pain
pathways and contribute to the development of daily headache.
Sarchielli et al.17 measured CSF levels
of nerve growth factor (NGF), CGRP and SP in patients with TM both with and
without medication overuse. Higher NGF, CGRP and SP levels were found in CSF in
both groups of patients compared with controls. A correlation was found between
NGF and SP levels. All levels correlated with the duration of the disorder.
This study suggests the involvement of NGF and chronic activation of the
trigeminal vascular system in TM. NGF production could arise from peripheral
trigeminal nerve terminals as well as the TNC and pain facilitating pathways. A
study by Ashina et al.18
strongly suggests that patients with an elevated CGRP level had TM and that the
trigeminal vascular system is activated as part of the process of TM.
Lance
observed that during migraine attacks patients complain of increased pain with
stimuli that would ordinarily be non-nociceptive. These stimuli include
hair-brushing, wearing a hat and resting the head on a pillow. This phenomenon
of pain being produced by non-painful stimuli is referred to as allodynia. In a
series of now-classic experiments, Burstein et al.19 explored allodynia
development in patients with migraine. He measured pain thresholds for hot,
cold and pressure stimuli, both within the region of spontaneous pain and
outside it. He found that as an attack progressed in a selected group of
migraine sufferers, cutaneous allodynia developed in the region of pain and
then outside it (extracephalic locations). He found that 33 of 42 patients (79
percent) developed allodynia. Allodynia began over the first half of the attack
in those who eventually developed it.
Peripheral Sensitization.
Sensitization of nociceptors results in an increased spontaneous neuronal
discharge rate. Neurons show increased responsiveness to both painful and
non-painful stimuli. The receptor fields expand and, as a result, pain is felt
over a greater part of the dermatome. This results in hyperalgesia (increased
sensitivity to pain) and cutaneous allodynia. An example of this is sunburn,
with increased sensitivity to temperature (i.e., a warm shower feels painfully
hot).
How does sensitization occur? Tissue
injuryJ and
inflammation result in the release of inflammatory mediators, such as
prostaglandin E2, bradykinin and NGF. These substances act on G-protein-coupled
receptors or tyrosine kinase receptors expressed on nociceptor terminals.K
This activates intracellular signaling pathways, resulting in phosphorylation
of receptors and ion channels. Phosphorylation changes the threshold and
kinetics of the nociceptor terminals, producing increased sensitivity and
excitability that results in peripheral sensitization.20 Transcriptional or
translational regulation can also contribute to peripheral sensitization.
NGF-induced activation of p38 mitogen-activated protein kinase in primary
sensory neurons after peripheral inflammation increases the expression and
peripheral transport of TRPV1 (a member of the transient receptor potential
family), exacerbating heat hyperalgesia.21
The
normal rhythmic pulsation of the meninges, which are innervated by peripheral
trigeminal neurons, can mediate the throbbing pain that migraineurs experience.
With the increase in intracranial neuronal sensitivity that migraine patients
experience, the normal rhythmic pulsation is interpreted as painful. Bendtsen
et al.22 has found
evidence for sensitization in CTTH patients. Pericranial myofascial tenderness,
evaluated by manual palpation, was considerably higher in patients than in
controls (p<0.00001). The stimulus-response function from highly tender
muscle was qualitatively different than from normal muscle, suggesting that
myofascial pain may be mediated by low-threshold mechanosensitive afferents
projecting to sensitized dorsal horn neurons.L
|
A: pericranial muscles includes the
muscles of
mastication, whose pathologic contraction intensity can exceed
voluntary
maximum during sleep. Other trigeminally innervated structures,
such as the TM joint and periodontal ligaments also provide
considerable nociceptive input
B: The third division
innervates a large portion of
pain-producing structures as well
D: which
includes the considerable noxious afferent activity created during
nocturnal trigeminally motor-innervated parafunction
E: both
sensory and motor dysfunction
F: excessive noxious
input from the
third division resulting from intense motor hyperactivity may also
influence normal sensory moduation
G: and perhaps due to excessive third division hyper motor
activity and resulting noxious activity
J:
perhaps
resulting from chronic nocturnal masticatory parafunction
K: therefore, a
therapeutic goal in the
prevention of migraine is to suppress the degree of trigeminal
nociception
L: and
possibly suggesing that myofascial pain and tenderness may be caused
and/or perpetuated by trigeminally innervated nocturnal hyper motor
activity
|
1. Silberstein SD, Lipton RB. Chronic daily headache
including
transformed migraine, chronic tension-type headache, and medication
overuse.
In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's headache and
other
head pain, Seventh ed. New York: Oxford University Press, 2001:247-282.
2. Mathew NT, Stubits E, Nigam MR. Transformation of
episodic
migraine into daily headache: analysis of factors. Headache
1982;22:66-68.
3. Mathew NT, Reuveni U, Perez F. Transformed or
evolutive
migraine. Headache 1987;27:102-106.
4. Rapoport AM. Analgesic rebound headache. Headache
1988;28:662-665.
5. Scher AI, Stewart WF, Liberman J, Lipton RB.
Prevalence of
frequent headache in a population sample. Headache 1998;38:497-506.
6. Castillo J, Munoz P, Guitera V, Pascual J.
Epidemiology of
chronic daily headache in the general population. Headache
1999;39:190-196.
7. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache
in
Chinese elderly: prevalence, risk factors and biannual follow-up.
Neurology
2000;54:314-319.
8. Headache Classification Committee. The International
Classification of Headache Disorders, 2nd Edition. Cephalalgia
2004;24:1-160.
9. Messlinger K, Burstein R. Anatomy of central nervous
system
pathways related to head pain. In: Olesen J, Tfelt-Hansen P, Welch KMA,
eds.
The headaches, 2nd ed. Philadelphia: Lippincott, Williams &
Wilkins,
1999:77.
10. Sweatt JD, Weeber EJ, Levenons JM. Central neural
mechanisms
that interrelate sensory and affective dimensions of pain. Mol Interven
2002;2:393-402.
11. Woolf CJ, Mitchell MB. Mechanism-based pain
diagnosis issues
for analgesic drug development. Anesthesiology 2001;95:241-249.
12. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current
understanding and treatment. N Engl J Med 2002 Jan 24;346:257-270.
13. Moskowitz MA. Basic mechanisms in vascular
headache. Neurol
Clin 1990;8:801-815.
14. Montalcini RL, Daltos R, Dellavalle F, et al.
Update of the
NGF saga. J Neurol Sci 1995;130:119-127.
15. Rang HP, Urban L. New molecules in analgesia. Br J
Anaesth
1995;75:145-156.
16. Edelman GM, Gally JA. Nitric oxide: linking space
and time
in the brain. Proc Natl Acad Sci USA 1992;89:1165111652.
17. Sarchielli P, Alberti A, Floridi A, Gallai V.
Levels of
nerve growth factor in cerebrospinal fluid of chronic daily headache
patients.
Neurology 2001 Jul 10;57:132-134.
18. Ashina M, Bendtsen L, Jensen R, Schifter S,
Jansen-Olesen I,
Olesen J. Plasma levels of calcitonin gene-related peptide in chronic
tension-type headache. Neurology 2000;55:1335-1340.
19. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ,
Bajwa ZH.
An association between migraine and cutaneous allodynia. Ann Neurol
2000;47:614-624.
20. Julius D, Basbaum AI. Molecular mechanisms of
nociception.
Nature 2001 Sep 13;413:203-210.
21. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38
MAPK
activation by NGF in primary sensory neurons after inflammation
increases TRPV1
levels and maintains heat hyperalgesia. Neuron 2002 Sep 26;36:57-68.
22. Bendtsen L, Jensen R, Olesen
J. Qualitatively altered
nociception in chronic myofascial pain. Pain 1996;65:259-264.
|